-
公开(公告)号：US20100267632A1
公开(公告)日：2010-10-21
申请号：US12284277
申请日：2008-09-19
申请人： Anton Haselbeck , Frank Herting , Joerg Huwyler , Michael Jarsch
发明人： Anton Haselbeck , Frank Herting , Joerg Huwyler , Michael Jarsch
IPC分类号： A61K38/22 , A61P25/28 , A61P25/18 , A61P25/16 , C07K14/505
CPC分类号： A61K38/1816 , A61K47/60
摘要： A method of treating neurodegenerative disorders of the brain and spinal cord is disclosed. The therapeutic agent is a polyethylene glycol linked protein.
摘要翻译： 公开了治疗脑和脊髓神经变性疾病的方法。 治疗剂是聚乙二醇连接的蛋白质。
-
公开(公告)号：US20070072795A1
公开(公告)日：2007-03-29
申请号：US11237505
申请日：2005-09-28
申请人： Anton Haselbeck , Frank Herting , Joerg Huwyler , Michael Jarsch
发明人： Anton Haselbeck , Frank Herting , Joerg Huwyler , Michael Jarsch
IPC分类号： A61K38/18
CPC分类号： A61K38/1816 , A61K47/60
摘要： A method of treating neurodegenerative disorders of the brain and spinal cord using a novel ethropoietic agent.
摘要翻译： 使用新型造血剂治疗脑和脊髓的神经变性疾病的方法。
-
3.发明申请COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) 审中-公开具有增加的抗体依赖性细胞毒性（ADCC）的II型抗CD20抗体的组合治疗公开(公告)号：US20110177067A1
公开(公告)日：2011-07-21
申请号：US13042305
申请日：2011-03-07
申请人： Charles Dumontet , Thomas Friess , Frank Herting , Christian Klein , Pablo Umana
发明人： Charles Dumontet , Thomas Friess , Frank Herting , Christian Klein , Pablo Umana
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/475 , A61K31/573 , A61K31/664 , A61K31/675 , A61K31/704 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/732 , A61K2300/00
摘要： The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.
摘要翻译： 本发明涉及药物组合物，其包含：（A）具有增加的抗体依赖性细胞毒性（ADCC）的II型抗CD20抗体; 和（B）选自环磷酰胺，长春新碱和多柔比星的化疗剂。 本发明还涉及一种用于治疗表达CD20的癌症的方法，包括对需要这种治疗的患者施用（i）有效的第一量的具有增加的抗体依赖性细胞毒性的II型抗CD20抗体; 和（ii）有效的第二量的一种或多种选自环磷酰胺，长春新碱和多柔比星的化学治疗剂。
-
公开(公告)号：US07638553B2
公开(公告)日：2009-12-29
申请号：US11628725
申请日：2005-06-13
申请人： Georg Fertig , Frank Herting , Matthias Koerner , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Ulrich Tibes
发明人： Georg Fertig , Frank Herting , Matthias Koerner , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Ulrich Tibes
IPC分类号： A61K31/381 , C07D333/22
CPC分类号： C07D333/38
摘要： Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明的目的是式（I）的化合物，其药学上可接受的盐，对映体形式，非对映异构体和外消旋物，上述化合物的制备，含有它们的药物及其制备，以及上述用途 用于控制或预防癌症等疾病的化合物。
-
公开(公告)号：US20080139640A1
公开(公告)日：2008-06-12
申请号：US11628725
申请日：2005-06-13
申请人： Georg Fertig , Frank Herting , Matthias Koerner , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Ulrich Tibes
发明人： Georg Fertig , Frank Herting , Matthias Koerner , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Ulrich Tibes
IPC分类号： A61K31/381 , C07D333/22 , A61P35/00
CPC分类号： C07D333/38
摘要： Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the In preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明的目的是式（I）的化合物，其药学上可接受的盐，对映体形式，非对映异构体和外消旋体。在制备上述化合物时，含有它们的药物及其制备方法以及使用 上述化合物在控制或预防诸如癌症的疾病中。
-
公开(公告)号：US07208491B2
公开(公告)日：2007-04-24
申请号：US10771188
申请日：2004-02-03
申请人： Georg Fertig , Frank Herting , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Michael Weidner
发明人： Georg Fertig , Frank Herting , Manfred Kubbies , Anja Limberg , Ulrike Reiff , Michael Weidner
IPC分类号： C07D333/56 , A61K31/5377 , A61K31/454 , A61K31/4439
CPC分类号： C07D333/70 , C07D209/42 , C07D307/85
摘要： Mono-acylated o-phenylendiamines derivatives of formula I wherein X and R are as described herein, have been found useful for the treatment of diseases mediated by the inhibition of histone deacetylase, such as cancer.
摘要翻译： 已经发现其中X和R如本文所述的式I的单酰化的邻苯基苯胺衍生物可用于治疗由组蛋白脱乙酰酶如癌症抑制介导的疾病。
-
公开(公告)号：US07098241B2
公开(公告)日：2006-08-29
申请号：US10732633
申请日：2003-12-10
申请人： Adelbert Grossmann , Frank Herting , Matthias Koerner , Klaus-Peter Kuenkele , Anja Limberg , Olaf Mundigl , Ulrich Tibes
发明人： Adelbert Grossmann , Frank Herting , Matthias Koerner , Klaus-Peter Kuenkele , Anja Limberg , Olaf Mundigl , Ulrich Tibes
IPC分类号： A61K31/38 , C07D333/22
CPC分类号： C07D409/12 , C07D333/38 , C07D413/12
摘要： The (R) and (S) enantiomers of a compound of formula I are novel antiproliferative therapeutic agents. These compounds have HDAC inhibitor activity and are useful in the treatment of cancer. Also disclosed are methods of making and using compounds of formula (I), as well as pharmaceutical compositions containing compounds of formula (I).
摘要翻译： 式I化合物的（R）和（S）对映异构体是新的抗增殖治疗剂。 这些化合物具有HDAC抑制剂活性，可用于治疗癌症。 还公开了制备和使用式（I）化合物的方法，以及含有式（I）化合物的药物组合物。
-
8.发明申请COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF ANTIBODY 审中-公开抗VEGF抗体的抗CD20抗体的组合疗法公开(公告)号：US20130183290A1
公开(公告)日：2013-07-18
申请号：US13211861
申请日：2011-08-17
申请人： Frank Herting , Christian Klein
发明人： Frank Herting , Christian Klein
IPC分类号： A61K39/395 , A61N5/10 , A61K45/06
CPC分类号： C07K16/3061 , A61K39/39558 , A61K45/06 , A61K2039/507 , A61N5/10 , C07K16/22 , C07K16/2887 , C07K2317/24 , C07K2317/41 , A61K2300/00
摘要： The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and an anti-VEGF antibody.
摘要翻译： 本发明涉及非岩藻糖基化抗CD20抗体与抗VEGF抗体用于治疗癌症的联合治疗，特别是与非糖蛋白化人源化B-Ly1抗体和抗VEGF的表达CD20的癌症的组合疗法 抗体。
-
9.发明申请COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE 审中-公开抗生素CD20抗体与BENDAMUSTINE的联合治疗公开(公告)号：US20120315268A1
公开(公告)日：2012-12-13
申请号：US13368465
申请日：2012-02-08
申请人： Frank Herting , Christian Klein
发明人： Frank Herting , Christian Klein
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/4184 , A61K45/06 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/41 , A61K2300/00
摘要： The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Lyl antibody and bendamustine.
摘要翻译： 本发明涉及非糖基化抗CD20抗体与苯达莫司汀用于治疗癌症的联合疗法，特别是与非糖蛋白化的人源化B-Lyl抗体和苯达莫司汀的CD20表达癌症的组合疗法。
-
10.发明申请COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) 审中-公开具有增加的抗体依赖性细胞毒性（ADCC）的II型抗CD20抗体的组合治疗公开(公告)号：US20120301459A1
公开(公告)日：2012-11-29
申请号：US13284415
申请日：2011-10-28
申请人： Charles Dumontet , Thomas Friess , Frank Herting , Christian Klein , Pablo Umana
发明人： Charles Dumontet , Thomas Friess , Frank Herting , Christian Klein , Pablo Umana
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/475 , A61K31/573 , A61K31/664 , A61K31/675 , A61K31/704 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/732 , A61K2300/00
摘要： The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.
摘要翻译： 本发明涉及药物组合物，其包含：（A）具有增加的抗体依赖性细胞毒性（ADCC）的II型抗CD20抗体; 和（B）选自环磷酰胺，长春新碱和多柔比星的化疗剂。 本发明还涉及一种用于治疗表达CD20的癌症的方法，包括对需要这种治疗的患者施用（i）有效的第一量的具有增加的抗体依赖性细胞毒性的II型抗CD20抗体; 和（ii）有效的第二量的一种或多种选自环磷酰胺，长春新碱和多柔比星的化学治疗剂。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.025 秒)
